oral semaglutide trials Oral Semaglutide Lowers HbA1c in Phase 3 Trial in Youth With Type 2 Diabetes

Now that oral semaglutide (#wegovy) is available, people want to know more about how the oral and injectable forms compare. First slide is the trial design. Second slide is average #weightloss of

26.20

★★★★☆4.8 (126)

🥼🧪Slide Deck: Efficacy and safety of oral semaglutide 25 mg in adults with overweight/obesity: the OASIS 4 RCT : r/Semaglutide

26.07

★★★★★4.9 (98)

Oral GLP-1 Pill Delivers Injection-Like Weight Loss Results in Clinical Trials

25.65

★★★★★5.0 (157)

Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials - Rubino - 2024 - Obesity

26.31

★★★★★4.7 (84)

At ADA 2025, the SOUL trial revealed that oral semaglutide (Rybelsus) reduced the risk of major cardiovascular events—like heart attack, stroke, and CV death—by 14% over ~4 years in type 2 diabetes

20.61

★★★★★4.9 (203)

Topline results from the phase 3 EVOKE and EVOKE+ studies of oral semaglutide in early Alzheimer's disease (AD) show that the trials did not meet their primary endpoints, Novo Nordisk announced. The

25.72

★★★★★5.0 (176)

The PIONEER program tested oral semaglutide — the first GLP-1 receptor agonist available as a pill rather than injection. Across multiple PIONEER trials in T2DM, oral semaglutide produced HbA1c and weight reductions

27.34

★★★★★4.8 (132)